Genetically engineered neural stem cells (NSCs) therapy for neurological diseases; state‐of‐the‐art

Neural stem cells (NSCs) are multipotent stem cells with remarkable self‐renewal potential and also unique competencies to differentiate into neurons, astrocytes, and oligodendrocytes (ODCs) and improve the cellular microenvironment. In addition, NSCs secret diversity of mediators, including neurotr...

Full description

Saved in:
Bibliographic Details
Published in:Biotechnology progress 2023-09, Vol.39 (5), p.e3363-n/a
Main Authors: Lutfi Ismaeel, Ghufran, Makki AlHassani, Olfet Jabbar, S. Alazragi, Reem, Hussein Ahmed, Ammar, H. Mohamed, Asma'a, Yasir Jasim, Nisreen, Hassan Shari, Falah, Almashhadani, Haider Abdulkareem
Format: Article
Language:English
Subjects:
Angiogenesis
Astrocytes
Biomolecules
Brain tumors
Brain-derived neurotrophic factor
Cell lineage
Disease
gene delivery
Genetic engineering
Genetic modification
Glial cell line-derived neurotrophic factor
Inflammation
Microenvironments
Nerve growth factor
Neural stem cells
neural stem cells (NSCs)
Neurodegenerative diseases
Neurogenesis
Neurological diseases
Oligodendrocytes
Oxidative stress
Pathogenesis
Stem cells
Transplantation
Vascular endothelial growth factor
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Neural stem cells (NSCs) are multipotent stem cells with remarkable self‐renewal potential and also unique competencies to differentiate into neurons, astrocytes, and oligodendrocytes (ODCs) and improve the cellular microenvironment. In addition, NSCs secret diversity of mediators, including neurotrophic factors (e.g., BDNF, NGF, GDNF, CNTF, and NT‐3), pro‐angiogenic mediators (e.g., FGF‐2 and VEGF), and anti‐inflammatory biomolecules. Thereby, NSCs transplantation has become a reasonable and effective treatment for various neurodegenerative disorders by their capacity to induce neurogenesis and vasculogenesis and dampen neuroinflammation and oxidative stress. Nonetheless, various drawbacks such as lower migration and survival and less differential capacity to a particular cell lineage concerning the disease pathogenesis hinder their application. Thus, genetic engineering of NSCs before transplantation is recently regarded as an innovative strategy to bypass these hurdles. Indeed, genetically modified NSCs could bring about more favored therapeutic influences post‐transplantation in vivo, making them an excellent option for neurological disease therapy. This review for the first time offers a comprehensive review of the therapeutic capability of genetically modified NSCs rather than naïve NSCs in neurological disease beyond brain tumors and sheds light on the recent progress and prospect in this context.
ISSN:8756-7938
1520-6033
DOI:10.1002/btpr.3363